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Abstract: 
The identification of specific target proteins for any diseased condition involves extensive characterization of the potentially involved proteins. Members of a 
protein family demonstrating comparable features may show certain unusual features when implicated in a pathological condition. Advancements in the field of 
computational biology and the use of various bioinformatics tools for analysis can aid researchers to comprehend their system of work in primary stages of 
research. This initial screening can help to reduce time and cost of testing and experimentation in laboratory. Human matrix metalloproteinase (MMP) family of 
endopeptidases is one such family of 23 members responsible for the remodeling of extracellular matrix (ECM) by degradation of the ECM proteins. Though their 
role has been implicated in various pathological conditions such as arthritis, atherosclerosis, cancer, liver fibrosis, cardio-vascular and neurodegenerative disorders, 
little is known about the specific involvement of members of the large MMP family in diseases. A comparative in silico characterization of the MMP protein 
family has been carried out to analyze their physico-chemical, secondary structural and functional properties. Based on the observed patterns of occurrence of 
atypical features, we hypothesize that cysteine rich and highly thermostable MMPs might be key players in diseased conditions. Thus, a plausible grouping of 
disease responsive MMPs that might be considered as promising clinical targets may be done. This study can be used as a fundamental approach to characterize, 
analyze and screen large protein families for the identification of signature patterns. 
 
 
 
 
Background: 
The past two decades have seen an exponential rise in the accumulation of 
genomic and proteomic data stored in the form of countless numbers of 
nucleotide and protein sequences in the data banks. Massive efforts by 
thousands of research scientists are being done to annotate the structures and 
functions of proteins in biological organisms. Conversely, the understanding of 
the function of newly discovered proteins that may potentially play a 
designated role in normal or diseased conditions is greatly aided by this 
amassing collection of data [1]. The systematic annotation of these protein 
sequences with the help of bioinformatics tools is one of the major thrust areas 
of application biology today. The progress in the field of bioinformatics is 
marked by the development of numerous tools through which the classification 
and identification of certain significant proteins has been made systematic and 
easier, thus saving the time and cost of experimentation by repeated trial and 
error in the laboratory. Such a prior analysis may also provide a direction to 
wet laboratory studies and thus help to integrate the fields of in silico and 
experimental work together. Protein families consist of proteins that have 
evolved during the course of time from a common ancestor and exhibit a 
threshold level of relationship [2]. MMPs are a family of zinc containing 
endopeptidases, which is a subset of the metzincin superfamily of 
metalloproteinases.  These regulatory proteases are the extracellular matrix 
(ECM) remodelers characterized by their substrate specificity to degrade ECM 
proteins. Based on this, they have been classified as collagenases, gelatinases, 
stromelysins, matrilysins, membrane type MMPs (MT-MMPs) and other 
unclassified MMPs [3]. Structurally, MMPs consist of four domains: an amino 
terminal hydrophobic pro- domain, a Zn
2+ containing catalytic domain, a 
flexible hinge region and a carboxy terminal hemopexin-like domain 
responsible for their substrate specific nature [4]. Activity of MMPs is 
regulated by Tissue Inhibitors of Matrix Metalloproteinases (TIMPs). Under 
normal conditions, this control is responsible for maintenance of the ECM. An 
imbalance in the regulation of activity may thus, disrupt the integrity of ECM 
[5]. MMPs have been implicated as clinical targets in numerous physiological 
and pathological conditions, such as arthritis, atherosclerosis, cancer, eye 
diseases, skin diseases, cardio-vascular and neurodegenerative disorders [6].  
 
Out of the 26 MMPs reported till date, 23 have been identified in humans [7]. 
Our study reports an in silico comparative characterization and analysis of 
human MMPs using various bio-computational tools, pertaining to their 
physico-chemical, secondary structural and functional features. Any atypical 
but significant feature may have various connotations with respect to the role of 
MMPs in pathological conditions. The aim here is to identify potential disease 
responsive MMPs that might possibly be implicated for their role in diseases. 
Moreover, such an in depth knowledge of all human MMPs would greatly aid 
researchers to identify the MMPs of interest relevant to their respective 
working systems. This would further set a precedent for similar comparative 
characterization studies for other large protein families, using the numerous 
resources from the field of computational biology. 
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Methodology: 
Protein sequence retrieval: 
UniProtKB/Swiss-Prot, a high quality manually annotated and non-redundant 
protein sequence database, was used to retrieve the complete sequences of the 
23 human MMPs [8]. These sequences were used for further analysis using 
various online bio-computational tools. 
 
Physico-chemical analysis: 
The computation of various physical and chemical parameters, such as amino 
acid composition, molecular weight, isoelectric point (pI), total number of 
negative and positive charged residues, extinction coefficient, instability index, 
aliphatic index and Grand Average of Hydropathy (GRAVY), was done using 
ExPASy’s ProtParam tool (http://us.expasy.org/ tools/protparam.html). 
ExPASy’s ProtScale tool was used to analyze the number of codons, bulkiness, 
polarity, refractivity, recognition factors, hydrophobicity, transmembrane 
tendency, percent buried residues, percent accessible residues, average area 
buried, average flexibility and relative mutability 
(http://us.expasy.org/tools/protscale.html) [9]. 
 
Secondary structural analysis:   
SOPMA tool (Self-Optimized Prediction Method with Alignment) of NPS@ 
(Network Protein Sequence Analysis) server was used to characterize the 
secondary structural features of the proteins such as, alpha helix, 310 helix, Pi 
helix, beta bridge, extended strand, beta turn, bend region, random coil, 
ambiguous states and other states [10].  
 
Functional analysis: 
The analysis of the MMP motifs was done with the help of Motif Scan tool 
(http://myhits.isb-sib.ch/cgi-bin/motif_scan) [11]. The SOSUI server prediction 
yielded the transmembrane regions of the human MMPs, which were further 
classified as membrane bound and soluble proteins [12]. 
 
Results and Discussion: 
MMPs are secreted in latent form as pro-MMPs and these zymogens are 
required to be cleaved for activation. They are found to exhibit pro and active 
forms, characterized by a difference in molecular weights (Table 1 see 
Supplementary material). The exceptional behavior of MMP-12, with two 
active forms (45 kDa and 22 kDa), is because of an internal autolytic 
processing mechanism causing its carboxy terminal domain to be cleaved from 
its catalytic domain, thus yielding three products [13]. 
 
 
Figure 1: Percentage of cysteine residues in human MMPs computed by 
ExPASy’s ProtParam tool. The amino acid composition of the 23 human 
MMPs was analyzed. Cysteine showed an abnormal trend as the percentage of 
cysteine residues in MMP-2, 9 and 23 was found to be exceptionally high as 
compared to other MMPs. 
 
Analysis of amino acid composition indicates that while the percentage of 
cysteine residues in majority of MMPs lies in the range of 0.6-1.3%, MMP-2, 9 
and 23 show a significant rise with values 2.9, 2.7 and 2.8 percent, respectively 
(Figure 1)  (Table 2 See supplementary material). High percentage of 
cysteine residues in MMP-2 and 9 might be correlated with presence of 
cysteine switch motif and role of these MMPs in pathological conditions. These 
gelatinases have been previously implicated in carcinomas and cardio-vascular 
disorders.  High cysteine content of the unclassified MMP-23 might be 
attributed to the presence of cysteine array in its structure. Highly significant 
presence of cysteine suggests its role as a critical residue for MMP activity and 
thus these MMPs may be investigated for possible role in diseased conditions. 
Further analysis of the amino acid composition can help to locate amino acid 
presence at an unusual level and be correlated with specific pathological 
conditions [14].  
 
 
Figure 2: Distribution plot of Stable and Unstable MMPs as computed by 
ExPASy’s ProtParam tool. The instability index classified MMP - 1, 2, 3, 7, 8, 
10, 12, 13, 16, 19, 20, 26 and 27 as stable (Instability index <40) and MMP - 9, 
11, 14, 15, 17, 21, 23, 24, 25 and 28 as unstable (Instability index >40)   
metalloproteinases. 
 
 
Figure 3: Computation of aliphatic index by ExPASy’s ProtParam tool. The 
aliphatic index indicates the thermostability of proteins. MMP-23 was found to 
be the most thermostable MMP with a high aliphatic index of 83.59. 
 
Other physico-chemical parameters also signify the behavior of MMPs in 
different conditions (Table 3(a) and 3(b) see Supplementary material). pI 
values for majority of MMPs (MMP-7, 12, 14, 15, 16, 19, 20, 21, 23, 24, 25, 27 
and 28) lie in the alkaline range (pH>7) while for the others, (MMP-1, 2, 3, 8, 
9, 10, 11, 13, 17 and 26) it falls in the acidic range (pH<7). In addition to this, 
the instability index classifies MMP - 1, 2, 3, 7, 8, 10, 12, 13, 16, 19, 20, 26 
and 27 as stable (Instability index <40) and remaining as unstable 
metalloproteinases (Instability index <40) (Figure 2). Furthermore, aliphatic 
index, signifying the relative volume of protein occupied by aliphatic side 
chains helps to study thermo stable properties of an enzyme. It is found to span 
within a range of 61.09 to 83.59 (Figure 3). Stability of human MMPs in a 
small range suggests their unstable nature over wide temperature range, though 
MMP-23 is observed as the most thermostable MMP.  Moreover, high 
extinction coefficients are observed for MMP- 2, 15, 16, 21, 24 and 28, which 
is correlated with a high concentration of lysine, tryptophan and tyrosine 
residues in the sequence and may be useful in protein-protein and protein-
ligand interaction studies in solution. Hydrophobicity values range from -
0.6720 of MMP-19 (most hydrophilic) to 0.4615 of MMP-14 (most 
hydrophobic). 
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Secondary structural analysis indicates a pre-dominance of random coils, 
followed by α-helices, extended strands and β-turns in 20 MMPs while the 
extended strands exceed α-helices in MMP-9, 11 and 19 (Figure 4) (Table 4 
see Supplementary material). This is useful to predict three dimensional 
structures of proteins and can help in approximation of some aspects of protein 
function and their classification into families [15].  
 
 
Figure 4: Analysis of secondary structural features through SOPMA. The 
computation of 23 human MMPs showed a pre-dominance of random coils, 
followed by α-helices, extended strands and β-turns in 20 MMPs, while 
extended strands exceeded α-helices in MMP-9, 11 and 19. The figure shows 
an average plot of the data of all 23 human MMPs.  
 
The Motif Scan tool predicts the presence of a cysteine switch, a zinc protease 
and a hemopexin motif in human MMPs which have been the subject of 
discussion in various literatures (Table 5 see Supplementary material). The 
cysteine switch regulates activity of MMPs via complex formation between 
cysteine residue of prodomain and zinc atom of catalytic domain [16]. The 
hemopexin domain is an essential part of MMPs performing multiple functions 
in activation and inhibition, homodimerization and multimerization, binding 
and cleavage of substrates, attachment to cell surface and degradation of MMPs 
[17]. The primary sequence motif HExxH is present in the catalytic domain of 
zinc-dependant MMPs. While the two conserved histidine residues coordinate 
the zinc atom, the glutamic acid residue is a member of the active site of 
enzyme  [18]. The zinc binding region signature has been defined as 
(uncharged)-(uncharged)-H-E-(uncharged)-(uncharged)-H-(uncharged)-(hydro 
phobic) [19]. Furthermore, an extra type II domain of fibronectin is found in 
MMP-2 and 9 at three regions within the catalytic domain, playing a pivotal 
role in the collagen binding region of these enzymes. MMP-17, 19, 21, 23, 25, 
26 and 28, classified as ‘other MMPs’, show the presence of zinc protease 
motif only. Also, transmembrane regions of length 20-23 base pairs are 
predicted in 14 MMPs using SOSUI server (Table 6 see Supplementary 
material). MMP-15, 16, 24 and 25 are found to possess two transmembrane 
regions. 
 
Conclusion: 
Intensive characterization and comparative analysis of the MMP family of 
proteins with the help of numerous bio-computational tools yielded new 
insights and perspectives which can be used to identify and group MMPs that 
play a crucial role in a pathological condition. In this study, physico-chemical, 
secondary structural and functional analysis of the large human MMP family 
was carried out. The findings through this study may be used by researchers 
working on MMPs in context of any experimental system. The amino acid 
composition shows a considerably high percentage of cysteine residues in 
MMP-23, along with MMP-2 and 9. Also, MMP 23 is found to be the most 
thermo stable MMP. We, thus, hypothesize that MMP-23, along with MMP-2 
and 9, might be a key player in pathological conditions. Further studies with 
the help of experimental research and testing need to be carried out to validate 
this proposal. In this manner, certain other groupings and clustering of disease 
responsive MMPs can be made by analysis of the various parameters of MMPs 
computed using bioinformatics tools. Additionally, this study may be taken as a 
prototype for similar in silico investigational studies with regard to other large 
proteins families, wherein such comparative analysis might aid in giving a 
direction and help to streamline the conduct of experimentation 
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Supplementary material: 
 
Table 1:  Functional properties and molecular weights of human MMPs 
MMP Accession 
No. 
Function  Mol. Wt (kDa) 
Pro form  Active form 
MMP-1  P03956  Cleaves collagens- I, II, III,VII,X  55  45 
MMP-2  P08253  Remodeling of vasculature, angiogenesis, tissue repair, tumor invasion, 
inflammation, atherosclerotic plaque rupture, degradation of ECM, myocardial cell 
death etc. 
72 66 
MMP-3  P08254  Degrades fibronectin, laminin, gelatins-I, III, IV,V; collagens-III, IV, X, IX & 
cartilage proteoglycans 
57 45 
MMP-7  P09237  Degrades casein, gelatin-I,III,IV,V & fibronectin  28  19 
MMP-8 P22894  Degrade  fibrillar  collagens- I,II,III  75  58 
MMP-9  P14780  Local proteolysis of ECM, leukocyte migration; cleaves fibronectin, collagen- IV,V  92  86 
MMP-10  P09238  Degrade fibronectin, gelatin-I,III,IV,V, collagens-III, IV,V  57  44 
MMP-11  P24347  Progression of epithelial malignancies  51  44 
MMP-12  P39900  Tissue injury & remodeling, significant elastolytic activity  54  45, 22 
MMP-13  P45452  Degrades collagen-I; may be involved in tumoral process  60  48 
MMP-14  P50281  Specifically activate progelatinase A; trigger invasion by tumor cells on the tumor 
cell surface 
66 56 
MMP-15  P51511  Degrades ECM components; may activate progelatinase A  72  50 
MMP-16  P51512  Degrades collagen-III & fibronectin; activates progelatinase A; ECM remodeling 
of blood vessels 
64 52 
MMP-17  Q9ULZ9  Degrades fibrin; may be involved in the activation of membrane-bound precursors 
of growth factors or inflammatory mediators 
57 53 
MMP-19  Q99542  Degrades aggrecan, collagen-IV, laminin, nidogen, nascin-C isoform, fibronectin & 
type I gelatin; May play role in neovascularization or angiogenesis 
54 45 
MMP-20 O60882  Degrades  amelogenin,  aggrecan & cartilage oligomeric matrix protein (COMP)  54  22 
MMP-21  Q8N119  May function in tumor progression & embryogenesis; cleaves alpha-1-antitrypsin  62  49 
MMP-23  O75900  Degrades ECM components  28  19 
MMP-24  Q9Y5R2  Activates progelatinase A; may cleave proteoglycans, fibronectin  57  53 
MMP-25  Q9NPA2  May activate progelatinase A  34  28 
MMP-26  Q9NRE1  May hydrolyze collagen-IV, fibronectin, fibrinogen, beta-casein, type I gelatin & 
alpha-1 proteinase inhibitor; activates progelatinase B 
28 19 
MMP-27  Q9H306  Degrades ECM components  N.D.  N.D. 
MMP-28  Q9H239  Degrades casein; could play role in tissue homeostasis & repair  56  45 
 
Table 2: Amino acid composition of human MMPs (in %) 
MMP Ala  Arg Asn Asp Cys Gln Glu  Gly  His Ile  Leu  Lys Met Phe Pro  Ser Thr Trp Tyr Val 
MMP-
1 
5.8  5.1 4.7 7.0 0.6 4.9 5.3 7.5  3.4  3.8  6.8 6.4  2.1  7.7  6.4  4.5  5.3  1.7  4.7  6.2 
MMP-
2 
7.1  3.9 3.6 8.2 2.9 2.9 5.0 10.0  1.5  3.8  7.1 6.8  1.8  7.1  6.7  4.4  6.4  2.3  4.5  3.9 
MMP-
3 
6.1  4.8 3.4 7.5 1.0 1.9 6.3 6.7  2.7  4.4  9.0 6.9  1.5  6.7  7.8  6.1  5.7  1.7  3.6  6.3 
MMP-
7 
6.7  4.5 4.1 6.0 1.1 3.4 4.5 9.7  3.0  4.1  10.1  6.4  3.4  4.1  6.0  7.1  4.9  1.9  4.1  4.9 
MMP-
8 
6.4  5.1 5.4 5.8 0.6 5.6 4.7 7.1  2.1  5.4  7.7 4.7  1.7  7.9  6.6  7.1  5.1  1.7  5.1  4.1 
MMP-
9 
7.2  6.9 2.0 7.6 2.7 3.7 4.1 9.5  2.0  2.0  8.8 3.1  1.3  6.2  8.3  6.2  7.1  2.0  3.8  5.5 
MMP-
10 
7.4  4.2 3.2 6.9 1.1 2.7 6.5 6.3  3.2  3.6  9.0 6.1  2.1  7.6  6.9  7.6  4.2  1.9  4.4  5.3 
MMP-
11 
11.3  7.6 0.8 6.8 0.8 4.3 4.3 7.8  3.5  2.3  9.8 2.5  1.0  6.1  10.7  4.1  4.7  3.3  2.9  5.5 
MMP-
12 
5.1  4.5 6.0 6.0 0.6 3.0 4.5 7.4  3.0  5.3  8.5 7.0  2.6  8.1  5.7  6.2  5.1  1.7  4.9  4.9 
MMP-
13 
5.3  4.0 3.8 8.7 0.8 1.7 5.7 7.4  3.8  5.1  9.1 6.2  2.5  6.8  7.0  6.4  4.7  2.1  4.5  4.2 
MMP-
14 
7.4  6.5 3.6 5.3 1.0 3.3 6.5 9.1  2.1  4.0  7.6 5.5  2.6  6.4  7.7  5.2  4.5  2.2  4.3  5.3 
MMP-
15 
6.4  8.4 3.0 6.1 0.9 4.0 5.7 10.2  2.7  2.4  8.7 3.3  2.4  5.1  10.2  3.7  4.0  2.8  3.9  6.1 BIOINFORMATION  open access 
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MMP-
16 
4.1  5.4 4.1 6.8 1.3 3.3 4.0 8.1  3.0  5.9  6.4 6.4  2.5  5.9  9.2  4.3  6.3  2.6  4.4  5.9 
MMP-
17 
10.6  7.3 1.3 7.6 1.0 3.6 4.0 8.5  3.8  1.7  9.3 2.5  1.7  4.5  10.1  6.5  4.6  2.7  3.5  5.3 
MMP-
19 
6.9  6.1 3.5 5.1 1.0 4.3 5.5 8.1  2.6  2.8  9.8 4.5  2.0  4.9  8.3  6.3  6.1  2.8  4.1  5.3 
MMP-
20 
7.7  4.8 3.5 5.4 0.6 3.1 5.0 7.9  2.9  4.1  7.0 6.8  2.9  6.0  6.4  7.0  6.0  1.4  5.4  6.0 
MMP-
21 
9.1  8.4 3.7 6.2 0.9 3.9 4.4 6.5  2.3  4.4  7.7 3.9  1.2  6.2  9.1  7.4  3.7  3.5  3.9  3.7 
MMP-
23 
10.3  10.5  1.8 3.6 2.8 2.1 3.8 7.7  4.1  2.1  11.8  2.6  1.3  4.4  7.9  5.1  5.1  3.1  3.3  6.7 
MMP-
24 
7.9  7.9 2.9 5.1 1.2 4.0 5.4 8.2  2.6  4.2  7.0 5.3  1.6  4.8  10.1  4.3  4.3  2.6  4.5  5.9 
MMP-
25 
8.5  8.2 1.4 6.2 1.1 5.2 4.1 8.5  2.3  2.0  10.0  3.0  1.6  4.8  12.1  6.2  4.3  2.7  2.8  5.0 
MMP-
26 
4.6  2.3 4.2 6.9 1.5 6.9 2.7 7.3  6.5  5.7  8.4 3.8  1.9  5.4  6.9  7.3  5.4  3.4  3.4  5.4 
MMP-
27 
5.7  5.3 3.9 6.2 1.2 3.3 4.7 7.2  2.7  7.0  8.2 7.0  2.5  8.2  5.7  4.9  6.0  1.8  4.1  4.5 
MMP-
28 
10.0  9.6 2.3 5.2 1.0 4.8 4.6 9.0  2.7  2.1  11.0  3.5  1.0  5.4  7.1  5.4  3.5  3.7  3.3  5.0 
 
Table 3(a): Physico-chemical parameters of human MMPs 
MMP No.  of 
A.A. 
M.W  
(Da) 
pI "-"  charged 
residues 
"+" 
charged 
residues 
Extinction 
coefficient 
Instability 
index 
Aliphatic 
index 
GRAVY 
MMP-1  469  54007  6.47  58 54 76905 35.46 65.27  -0.572 
MMP-2  660  73882  5.26  87 71 128325  27.46 61.09  -0.446 
MMP-3  477  53977  5.77  66 56 69580 27.9  76.65  -0.386 
MMP-7  267  29677  7.73  28 29 44015 32.39 76.37  -0.369 
MMP-8  467  53412  6.38  49 46 79885 29.47 69.16  -0.451 
MMP-9  707  78458  5.69  83 71 118355  41.10 65.13  -0.394 
MMP-10  476  54151  5.49  64 49 81040 34.39 71.74  -0.370 
MMP-11  488  54618  6.38  54 49 109110  51.79 74.47  -0.327 
MMP-12  470  54002  8.75  49 54 78395 25.91 73.23  -0.383 
MMP-13  471  53820  5.32  68 48 86540 20.36 73.10  -0.435 
MMP-14  582  65884  7.63  69 70 109125  47.75 67.73  -0.464 
MMP-15  669  75807  7.03  79 78 143615  44.36 67.34  -0.567 
MMP-16  607  69521  8.72  65 72 128730  36.13 69.51  -0.484 
MMP-17  603  66653  6.08  70 59 119665  46.90 68.69  -0.454 
MMP-19  508  57357  7.22  54 54 108540  35.90 71.44  -0.472 
MMP-20  483  54360  8.84  50 56 77365 26.53 68.67  -0.401 
MMP-21  569  65015  9.19  60 70 143030  45.06 67.14  -0.547 
MMP-23  390  43935  9.94  29 51 85995 55.08 83.59  -0.183 
MMP-24  645  73231  9.30  68 85 137210  50.21 68.53  -0.562 
MMP-25  562  62554  8.76  58 63 106715  51.82 69.48  -0.499 
MMP-26  261  29708  5.96  25 16 63160 29.25 75.44  -0.385 
MMP-27  513  59026  8.83  56 63 81165 25.03 77.95  -0.278 
MMP-28  520  58939  9.70  51 68 130080  49.47 75.50  -0.444 
 
Table 3(b): Physico-chemical parameters of human MMPs 
MMP No.  of 
codons 
Bulkiness Polarity Refracti
vity 
Recogniti
on 
factors 
Hydrop
hobicity 
Transme
mbrane 
tendency 
% 
buried 
residues 
% 
accessible 
residues 
Avg area 
buried 
Avg 
flexibility 
Relative 
Mutability 
MMP-1 3.6110  15.1460 19.783 16.5695  87.0000 -0.1110  -0.2305 5.9945 5.5165  125.6165 0.4470  70.2775 
MMP-2 3.5000  14.0970 19.827 16.1855  87.1115 -0.2110  -0.7410 5.7780 5.6665  128.3280 0.4340  70.8890 
MMP-3  3.5555  15.3020 17.268 16.7545  89.3890 0.3280 -0.4410  6.2830 5.9835  127.0220  0.4365  74.1110 
MMP-7 3.7220  14.1535 19.810 15.4755  88.1670 -0.0165  -0.5925 6.1055 6.0390  123.9110 0.4380  78.2225 
MMP-8 3.3890  14.7670 17.577 17.3755  87.1110 -0.2220  -0.3885 5.4445 6.0500  129.4615 0.4395  74.7780 
MMP-9  3.7220  15.4210 17.065 17.2705  88.7780 0.4000 -0.2795  7.0610 5.6335  123.6555  0.4425  73.2220 
MMP-10  3.3335  15.5170 19.693 18.9495  88.4445 0.2115 -0.4760  6.1720 6.0280  133.1720  0.4185  76.0000 
MMP-11  3.6665  15.9240 17.456 16.6195  87.8890 -0.1220  -0.2640 6.0335 5.3280  127.3445 0.4305  71.1110 
MMP-12  3.5000  14.2855 16.941 16.5455  88.5000 -0.1615  -0.2895 5.5610 5.6220  128.8555 0.4475  76.2225 
MMP-13  3.5555  14.4015 19.529 17.6950  88.6665 -0.1055  -0.5055 6.1725 5.6275  129.4775 0.4365  80.0555 
MMP-14  3.6110  15.3545 17.051 16.1120  89.1110 0.4615 -0.2935  7.0445 5.5890  129.2110  0.4460  73.6110 
MMP-15  3.7780  14.9395 17.583 16.5930  87.2220 0.0725 -0.3135  6.3275 5.3445  126.7835  0.4450  74.2780 
MMP-16  3.3890  15.2295 17.297 16.7755  88.1670 0.0835 -0.5865  6.4170 5.4665  128.0390  0.4405  74.2775 
MMP-17  3.8335  15.1760 17.463 15.7685  88.5000 0.0000 -0.3615  6.5720 5.4110  123.0110  0.4450  69.7225 
MMP-19  3.5000  14.2875 22.683 15.5570  88.3335 -0.6720  -0.7225 6.1835 5.1780  123.2445 0.4410  70.5000 
MMP-20  3.5000  14.3375 22.541 16.4980  89.7775 -0.0500  -0.5680 5.8335 5.6000  127.3500 0.4325  73.1110 
MMP-21  3.8335  14.6015 19.892 18.0500  88.2775 -0.5500  -0.6645 5.9665 5.7555  129.3940 0.4415  73.0000 
MMP-23  3.5555  15.3540 17.265 16.5920  88.2225 0.3665 -0.2880  6.9280 5.3500  125.1945  0.4280  74.6665 
MMP-24  3.7225  14.9800 22.630 15.5350  88.0555 -0.1445  -0.5225 6.3275 5.4775  126.6665 0.4450  72.6665 BIOINFORMATION  open access 
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MMP-25  3.9445  15.1620 16.949 17.4410  88.7775 0.4335 -0.1095  6.9330 5.6720  127.9275  0.4375  70.3890 
MMP-26  3.3335  15.4225 14.731 16.3125  89.0555 0.1445 -0.1935  6.0445 5.3555  126.4890  0.4360  74.3335 
MMP-27  3.2780  15.6320 17.096 17.2455  87.1665 0.3000 -0.1730  6.0000 5.1500  130.9555  0.4340  74.4445 
MMP-28  3.7220  14.2075 20.412 16.7435  88.5555 -0.5500  -0.6835 5.7720 5.1555  127.7220 0.4420  70.1110 
 
Table 4: Secondary structural features of human MMPs (in %) 
MMP  α helix  310 helix Pi  helix β bridge  Extended strand  β turn  Bend 
region 
Random 
coil 
Ambigous 
states 
Other 
states 
MMP-1  23.03  0 0 0  21.54  8.32  0  47.12  0  0 
MMP-2  23.18  0 0 0  21.52  10.76  0  44.55  0  0 
MMP-3  24.74  0 0 0  20.75  9.01  0  45.49  0  0 
MMP-7  33.71  0 0 0  14.98  4.87  0  46.44  0  0 
MMP-8  23.77  0 0 0  20.56  7.71  0  47.97  0  0 
MMP-9  17.40  0 0 0  21.92  8.35  0  52.33  0  0 
MMP-10  24.37  0 0 0  20.38  8.61  0  46.64  0  0 
MMP-11  17.83  0 0 0  19.26  7.17  0  55.74  0  0 
MMP-12  23.19  0 0 0  20.00  7.02  0  49.79  0  0 
MMP-13  23.99  0 0 0  21.44  7.64  0  46.92  0  0 
MMP-14  23.71  0 0 0  19.24  7.90  0  49.14  0  0 
MMP-15  24.96  0 0 0  18.54  8.82  0  47.68  0  0 
MMP-16  23.23  0 0 0  20.26  7.74  0  48.76  0  0 
MMP-17  18.74  0 0 0  16.09  8.79  0  56.38  0  0 
MMP-19  19.69  0 0 0  20.67  8.66  0  50.98  0  0 
MMP-20  23.19  0 0 0  17.81  7.45  0  51.55  0  0 
MMP-21  22.14  0 0 0  17.40  8.26  0  52.20  0  0 
MMP-23  32.82  0 0 0  20.26  7.44  0  39.49  0  0 
MMP-24  23.57  0 0 0  16.74  7.13  0  52.56  0  0 
MMP-25  24.02  0 0 0  15.66  5.69  0  54.63  0  0 
MMP-26  27.97  0 0 0  16.09  3.07  0  52.87  0  0 
MMP-27  26.32  0 0 0  20.47  8.38  0  44.83  0  0 
MMP-28  25.38  0 0 0  17.12  7.50  0  50.00  0  0 
 
Table 5: Motifs of human MMPs 
MMP  Motif found  Motif ID  Description  Start  End 
MMP-1 CYSTEINE_SWITCH  PS00546  Matrixins  cysteine  switch  90  97 
HEMOPEXIN  PS00024  Hemopexin domain signature  317  332 
ZINC_PROTEASE  PS00142  Neutral zinc metallopeptidases, zinc-binding region 
signature 
215 224 
MMP-2 CYSTEINE_SWITCH  PS00546  Matrixins  cysteine  switch  100  107 
HEMOPEXIN  PS00024  Hemopexin domain signature  606  621 
FN2_1  PS00023  Fibronectin type-II collagen-binding domain signature  233  274 
291 332 
349 390 
ZINC_PROTEASE  PS00142  Neutral zinc metallopeptidases, zinc-binding region 
signature 
400 409 
MMP-3 CYSTEINE_SWITCH  PS00546  Matrixins  cysteine  switch  90  97 
HEMOPEXIN  PS00024  Hemopexin domain signature  329  344 
ZINC_PROTEASE  PS00142  Neutral zinc metallopeptidases, zinc-binding region 
signature 
215 224 
MMP-7 CYSTEINE_SWITCH  PS00546  Matrixins  cysteine  switch  85  92 
ZINC_PROTEASE  PS00142  Neutral zinc metallopeptidases, zinc-binding region 
signature 
211 220 
MMP-8 CYSTEINE_SWITCH  PS00546  Matrixins  cysteine  switch  89  96 
HEMOPEXIN  PS00024  Hemopexin domain signature  318  333 
ZINC_PROTEASE  PS00142  Neutral zinc metallopeptidases, zinc-binding region 
signature 
214 223 
MMP-9 CYSTEINE_SWITCH  PS00546  Matrixins  cysteine  switch  97  104 
HEMOPEXIN  PS00024  Hemopexin domain signature  556  571 
FN2_1  PS00023  Fibronectin type-II collagen-binding domain signature  230  271 
288 329 
347 388 
ZINC_PROTEASE  PS00142  Neutral zinc metallopeptidases, zinc-binding region 
signature 
398 407 
MMP-10 CYSTEINE_SWITCH  PS00546  Matrixins  cysteine  switch  89  96 
HEMOPEXIN  PS00024  Hemopexin domain signature  328  343 
ZINC_PROTEASE  PS00142  Neutral zinc metallopeptidases, zinc-binding region 
signature 
214 223 
MMP-11 CYSTEINE_SWITCH  PS00546  Matrixins  cysteine  switch  78  85 
HEMOPEXIN  PS00024  Hemopexin domain signature  332  347 BIOINFORMATION  open access 
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ZINC_PROTEASE  PS00142  Neutral zinc metallopeptidases, zinc-binding region 
signature 
212 221 
MMP-12 CYSTEINE_SWITCH  PS00546  Matrixins  cysteine  switch  90  97 
HEMOPEXIN  PS00024  Hemopexin domain signature  321  336 
ZINC_PROTEASE  PS00142  Neutral zinc metallopeptidases, zinc-binding region 
signature 
215 224 
MMP-13 CYSTEINE_SWITCH  PS00546  Matrixins  cysteine  switch  94  101 
HEMOPEXIN  PS00024  Hemopexin domain signature  323  338 
ZINC_PROTEASE  PS00142  Neutral zinc metallopeptidases, zinc-binding region 
signature 
219 228 
MMP-14 CYSTEINE_SWITCH  PS00546  Matrixins  cysteine  switch  91  98 
HEMOPEXIN  PS00024  Hemopexin domain signature.  357  372 
ZINC_PROTEASE  PS00142  Neutral zinc metallopeptidases, zinc-binding region 
signature. 
236 245 
MMP-15 CYSTEINE_SWITCH  PS00546  Matrixins  cysteine  switch  109  116 
HEMOPEXIN  PS00024  Hemopexin domain signature  408  423 
ZINC_PROTEASE  PS00142  Neutral zinc metallopeptidases, zinc-binding region 
signature 
256 265 
MMP-16 CYSTEINE_SWITCH  PS00546  Matrixins  cysteine  switch  99  106 
HEMOPEXIN  PS00024  Hemopexin domain signature  381  396 
ZINC_PROTEASE  PS00142  Neutral zinc metallopeptidases, zinc-binding region 
signature 
243 252 
MMP-17 ZINC_PROTEASE  PS00142  Neutral  zinc  metallopeptidases, zinc-binding region 
signature 
245 254 
MMP-19 ZINC_PROTEASE  PS00142  Neutral  zinc  metallopeptidases, zinc-binding region 
signature 
209 218 
MMP-20 CYSTEINE_SWITCH  PS00546  Matrixins  cysteine  switch  98  105 
ZINC_PROTEASE  PS00142  Neutral zinc metallopeptidases, zinc-binding region 
signature 
223 232 
MMP-21 ZINC_PROTEASE  PS00142  Neutral  zinc  metallopeptidases, zinc-binding region 
signature 
280 289 
MMP-23 ZINC_PROTEASE  PS00142  Neutral  zinc  metallopeptidases, zinc-binding region 
signature 
208 217 
MMP-24  HEMOPEXIN  PS00024  Hemopexin domain signature  418  433 
ZINC_PROTEASE  PS00142  Neutral zinc metallopeptidases, zinc-binding region 
signature 
279 288 
MMP-25 ZINC_PROTEASE  PS00142  Neutral  zinc  metallopeptidases, zinc-binding region 
signature 
230 239 
MMP-26 ZINC_PROTEASE  PS00142  Neutral  zinc  metallopeptidases, zinc-binding region 
signature 
205 214 
MMP-27 CYSTEINE_SWITCH  PS00546  Matrixins  cysteine  switch  89  96 
HEMOPEXIN  PS00024  Hemopexin domain signature  318  333 
ZINC_PROTEASE  PS00142  Neutral zinc metallopeptidases, zinc-binding region 
signature 
213 222 
MMP-28 ZINC_PROTEASE  PS00142  Neutral  zinc  metallopeptidases, zinc-binding region 
signature 
237 246 
 
Table 6: Transmembrane regions of human MMPs 
MMP  Nature of protein  N terminal  Transmembrane region  C terminal  Length  Type 
MMP-1  Soluble - -  - -  - 
MMP-2  Soluble - -  - -  - 
MMP-3 Transmembrane  2  KSLPILLLLCVAVCSAYPLDGAA  24  23  Primary 
MMP-7 Transmembrane  1  MRLTVLCAVCLLPGSLALPLPQE  23  23  Primary 
MMP-8  Soluble -   - -  - 
MMP-9 Transmembrane  1  MSLWQPLVLVLLVLGCCFAA  20  20  Primary 
MMP-10 Transmembrane  2  MHLAFLVLLCLPVCSAYPLSGAA  24  23  Primary 
MMP-11  Soluble - -  - -  - 
MMP-12  Soluble - -  - -  - 
MMP-13  Soluble - -  - -  - 
MMP-14 Transmembrane  532  EGGGAVSAAAVVLPVLLLLLVLA 554  23  Primary 
MMP-15  Transmembrane  28 RLLPLLLVLLGCLGLGVAAED  48 21  Secondary 
619 EVARTVNVVMVLVPLLLLLCVLG  641 23  Primary 
MMP-16 Transmembrane  15  VHHSGVFFLQTLLWILCATVCGT 37  23  Secondary 
561 TVKAIAIVIPCILALCLLVLVYT  583 23  Primary 
MMP-17  Soluble - -  - -  - 
MMP-19  Soluble - -  - -  - 
MMP-20  Soluble - -  - -  - 
MMP-21 Transmembrane  1  MLAASIFRPTLLLCWLAAPW  20  20  Primary 
MMP-23  Transmembrane  31 LPALVLLARLGAPAVPAWSAAQG  53 23  Primary 
MMP-24  Transmembrane  34 RLLLLLLPALCCLPGAARAAAAA  56 23  Secondary BIOINFORMATION  open access 
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598 GSVNAVAVVIPCILSLCILVLVY  620 23  Primary 
MMP-25 Transmembrane  6  RLLALLLLLLAPPARAPKPSAQD  28  23  Primary 
541 GRWPAPIPLLLLPLLVGGVASR  562 22  Primary 
MMP-26 Transmembrane  2  QLVILRVTIFLPWCFAVPVPPAA  24  23  Primary 
MMP-27 Transmembrane  4  LLLLFLFFITFSSAFPLVRMT  24  21  Primary 
MMP-28 Transmembrane  1  MVARVGLLLRALQLLLWGHLDAQ  23  23  Primary 
*(-) – Does not exist. 